A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
Background The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment. Methods We conducted an open-...
Saved in:
| Published in | Journal of hematology and oncology Vol. 18; no. 1; pp. 3 - 10 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
05.01.2025
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1756-8722 1756-8722 |
| DOI | 10.1186/s13045-024-01656-0 |
Cover
| Abstract | Background
The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment.
Methods
We conducted an open-label, single-arm, multicenter, phase II trial in China. Eligible patients were 18–75 years old with histologically or cytologically confirmed NSCLC who were EGFR mutation positive and showed gradual, oligo, or potential progression after EGFR-TKIs. Anlotinib (12 mg/day) was administered orally for 2 weeks and then off 1 week in a 3-week cycle. EGFR-TKIs were continue used. The primary endpoint was progression-free survival (PFS). The secondary endpoints included 6- and 12-month PFS rate, objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety.
Results
From July 2019 to December 2022, 120 patients were enrolled. The median PFS (mPFS) was 9.1 months (95% CI 6.8–11.7). The PFS rates at 6 and 12 months was 68.5% and 38.8% respectively. For 86 patients with first-line 1st /2nd generation EGFR-TKIs, the mPFS was 9.2 months (95% CI 6.7–12.6). For 32 patients with first-line 3rd generation EGFR-TKIs, the mPFS was 10.3 months (95% CI 6.1–13.3). Overall ORR and DCR were 6.7% (95% CI 2.9–12.7) and 87.5% (95% CI 80.2–92.8), respectively. 52.5% of patients had grade 3 or higher treatment-emergent adverse events (TEAEs).
Conclusion
Anlotinib in combination with continuation of EGFR-TKIs prolonged the clinical benefit of EGFR-TKIs, demonstrating favorable survival outcomes and manageable toxicity in NSCLC treated with EGFR-TKIs and had specific progression modes, such as gradual progression.
Trial registration
NCT04007835. |
|---|---|
| AbstractList | BackgroundThe study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment.MethodsWe conducted an open-label, single-arm, multicenter, phase II trial in China. Eligible patients were 18–75 years old with histologically or cytologically confirmed NSCLC who were EGFR mutation positive and showed gradual, oligo, or potential progression after EGFR-TKIs. Anlotinib (12 mg/day) was administered orally for 2 weeks and then off 1 week in a 3-week cycle. EGFR-TKIs were continue used. The primary endpoint was progression-free survival (PFS). The secondary endpoints included 6- and 12-month PFS rate, objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety.ResultsFrom July 2019 to December 2022, 120 patients were enrolled. The median PFS (mPFS) was 9.1 months (95% CI 6.8–11.7). The PFS rates at 6 and 12 months was 68.5% and 38.8% respectively. For 86 patients with first-line 1st /2nd generation EGFR-TKIs, the mPFS was 9.2 months (95% CI 6.7–12.6). For 32 patients with first-line 3rd generation EGFR-TKIs, the mPFS was 10.3 months (95% CI 6.1–13.3). Overall ORR and DCR were 6.7% (95% CI 2.9–12.7) and 87.5% (95% CI 80.2–92.8), respectively. 52.5% of patients had grade 3 or higher treatment-emergent adverse events (TEAEs).ConclusionAnlotinib in combination with continuation of EGFR-TKIs prolonged the clinical benefit of EGFR-TKIs, demonstrating favorable survival outcomes and manageable toxicity in NSCLC treated with EGFR-TKIs and had specific progression modes, such as gradual progression.Trial registrationNCT04007835. The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment. We conducted an open-label, single-arm, multicenter, phase II trial in China. Eligible patients were 18-75 years old with histologically or cytologically confirmed NSCLC who were EGFR mutation positive and showed gradual, oligo, or potential progression after EGFR-TKIs. Anlotinib (12 mg/day) was administered orally for 2 weeks and then off 1 week in a 3-week cycle. EGFR-TKIs were continue used. The primary endpoint was progression-free survival (PFS). The secondary endpoints included 6- and 12-month PFS rate, objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety. From July 2019 to December 2022, 120 patients were enrolled. The median PFS (mPFS) was 9.1 months (95% CI 6.8-11.7). The PFS rates at 6 and 12 months was 68.5% and 38.8% respectively. For 86 patients with first-line 1st /2nd generation EGFR-TKIs, the mPFS was 9.2 months (95% CI 6.7-12.6). For 32 patients with first-line 3rd generation EGFR-TKIs, the mPFS was 10.3 months (95% CI 6.1-13.3). Overall ORR and DCR were 6.7% (95% CI 2.9-12.7) and 87.5% (95% CI 80.2-92.8), respectively. 52.5% of patients had grade 3 or higher treatment-emergent adverse events (TEAEs). Anlotinib in combination with continuation of EGFR-TKIs prolonged the clinical benefit of EGFR-TKIs, demonstrating favorable survival outcomes and manageable toxicity in NSCLC treated with EGFR-TKIs and had specific progression modes, such as gradual progression. Background The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment. Methods We conducted an open-label, single-arm, multicenter, phase II trial in China. Eligible patients were 18–75 years old with histologically or cytologically confirmed NSCLC who were EGFR mutation positive and showed gradual, oligo, or potential progression after EGFR-TKIs. Anlotinib (12 mg/day) was administered orally for 2 weeks and then off 1 week in a 3-week cycle. EGFR-TKIs were continue used. The primary endpoint was progression-free survival (PFS). The secondary endpoints included 6- and 12-month PFS rate, objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety. Results From July 2019 to December 2022, 120 patients were enrolled. The median PFS (mPFS) was 9.1 months (95% CI 6.8–11.7). The PFS rates at 6 and 12 months was 68.5% and 38.8% respectively. For 86 patients with first-line 1st /2nd generation EGFR-TKIs, the mPFS was 9.2 months (95% CI 6.7–12.6). For 32 patients with first-line 3rd generation EGFR-TKIs, the mPFS was 10.3 months (95% CI 6.1–13.3). Overall ORR and DCR were 6.7% (95% CI 2.9–12.7) and 87.5% (95% CI 80.2–92.8), respectively. 52.5% of patients had grade 3 or higher treatment-emergent adverse events (TEAEs). Conclusion Anlotinib in combination with continuation of EGFR-TKIs prolonged the clinical benefit of EGFR-TKIs, demonstrating favorable survival outcomes and manageable toxicity in NSCLC treated with EGFR-TKIs and had specific progression modes, such as gradual progression. Trial registration NCT04007835. The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment. We conducted an open-label, single-arm, multicenter, phase II trial in China. Eligible patients were 18-75 years old with histologically or cytologically confirmed NSCLC who were EGFR mutation positive and showed gradual, oligo, or potential progression after EGFR-TKIs. Anlotinib (12 mg/day) was administered orally for 2 weeks and then off 1 week in a 3-week cycle. EGFR-TKIs were continue used. The primary endpoint was progression-free survival (PFS). The secondary endpoints included 6- and 12-month PFS rate, objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety. From July 2019 to December 2022, 120 patients were enrolled. The median PFS (mPFS) was 9.1 months (95% CI 6.8-11.7). The PFS rates at 6 and 12 months was 68.5% and 38.8% respectively. For 86 patients with first-line 1st /2nd generation EGFR-TKIs, the mPFS was 9.2 months (95% CI 6.7-12.6). For 32 patients with first-line 3rd generation EGFR-TKIs, the mPFS was 10.3 months (95% CI 6.1-13.3). Overall ORR and DCR were 6.7% (95% CI 2.9-12.7) and 87.5% (95% CI 80.2-92.8), respectively. 52.5% of patients had grade 3 or higher treatment-emergent adverse events (TEAEs). Anlotinib in combination with continuation of EGFR-TKIs prolonged the clinical benefit of EGFR-TKIs, demonstrating favorable survival outcomes and manageable toxicity in NSCLC treated with EGFR-TKIs and had specific progression modes, such as gradual progression. NCT04007835. The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment.BACKGROUNDThe study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment.We conducted an open-label, single-arm, multicenter, phase II trial in China. Eligible patients were 18-75 years old with histologically or cytologically confirmed NSCLC who were EGFR mutation positive and showed gradual, oligo, or potential progression after EGFR-TKIs. Anlotinib (12 mg/day) was administered orally for 2 weeks and then off 1 week in a 3-week cycle. EGFR-TKIs were continue used. The primary endpoint was progression-free survival (PFS). The secondary endpoints included 6- and 12-month PFS rate, objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety.METHODSWe conducted an open-label, single-arm, multicenter, phase II trial in China. Eligible patients were 18-75 years old with histologically or cytologically confirmed NSCLC who were EGFR mutation positive and showed gradual, oligo, or potential progression after EGFR-TKIs. Anlotinib (12 mg/day) was administered orally for 2 weeks and then off 1 week in a 3-week cycle. EGFR-TKIs were continue used. The primary endpoint was progression-free survival (PFS). The secondary endpoints included 6- and 12-month PFS rate, objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety.From July 2019 to December 2022, 120 patients were enrolled. The median PFS (mPFS) was 9.1 months (95% CI 6.8-11.7). The PFS rates at 6 and 12 months was 68.5% and 38.8% respectively. For 86 patients with first-line 1st /2nd generation EGFR-TKIs, the mPFS was 9.2 months (95% CI 6.7-12.6). For 32 patients with first-line 3rd generation EGFR-TKIs, the mPFS was 10.3 months (95% CI 6.1-13.3). Overall ORR and DCR were 6.7% (95% CI 2.9-12.7) and 87.5% (95% CI 80.2-92.8), respectively. 52.5% of patients had grade 3 or higher treatment-emergent adverse events (TEAEs).RESULTSFrom July 2019 to December 2022, 120 patients were enrolled. The median PFS (mPFS) was 9.1 months (95% CI 6.8-11.7). The PFS rates at 6 and 12 months was 68.5% and 38.8% respectively. For 86 patients with first-line 1st /2nd generation EGFR-TKIs, the mPFS was 9.2 months (95% CI 6.7-12.6). For 32 patients with first-line 3rd generation EGFR-TKIs, the mPFS was 10.3 months (95% CI 6.1-13.3). Overall ORR and DCR were 6.7% (95% CI 2.9-12.7) and 87.5% (95% CI 80.2-92.8), respectively. 52.5% of patients had grade 3 or higher treatment-emergent adverse events (TEAEs).Anlotinib in combination with continuation of EGFR-TKIs prolonged the clinical benefit of EGFR-TKIs, demonstrating favorable survival outcomes and manageable toxicity in NSCLC treated with EGFR-TKIs and had specific progression modes, such as gradual progression.CONCLUSIONAnlotinib in combination with continuation of EGFR-TKIs prolonged the clinical benefit of EGFR-TKIs, demonstrating favorable survival outcomes and manageable toxicity in NSCLC treated with EGFR-TKIs and had specific progression modes, such as gradual progression.NCT04007835.TRIAL REGISTRATIONNCT04007835. Abstract Background The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment. Methods We conducted an open-label, single-arm, multicenter, phase II trial in China. Eligible patients were 18–75 years old with histologically or cytologically confirmed NSCLC who were EGFR mutation positive and showed gradual, oligo, or potential progression after EGFR-TKIs. Anlotinib (12 mg/day) was administered orally for 2 weeks and then off 1 week in a 3-week cycle. EGFR-TKIs were continue used. The primary endpoint was progression-free survival (PFS). The secondary endpoints included 6- and 12-month PFS rate, objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety. Results From July 2019 to December 2022, 120 patients were enrolled. The median PFS (mPFS) was 9.1 months (95% CI 6.8–11.7). The PFS rates at 6 and 12 months was 68.5% and 38.8% respectively. For 86 patients with first-line 1st /2nd generation EGFR-TKIs, the mPFS was 9.2 months (95% CI 6.7–12.6). For 32 patients with first-line 3rd generation EGFR-TKIs, the mPFS was 10.3 months (95% CI 6.1–13.3). Overall ORR and DCR were 6.7% (95% CI 2.9–12.7) and 87.5% (95% CI 80.2–92.8), respectively. 52.5% of patients had grade 3 or higher treatment-emergent adverse events (TEAEs). Conclusion Anlotinib in combination with continuation of EGFR-TKIs prolonged the clinical benefit of EGFR-TKIs, demonstrating favorable survival outcomes and manageable toxicity in NSCLC treated with EGFR-TKIs and had specific progression modes, such as gradual progression. Trial registration NCT04007835. Background The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potential progression after previous EGFR-TKIs treatment. Methods We conducted an open-label, single-arm, multicenter, phase II trial in China. Eligible patients were 18-75 years old with histologically or cytologically confirmed NSCLC who were EGFR mutation positive and showed gradual, oligo, or potential progression after EGFR-TKIs. Anlotinib (12 mg/day) was administered orally for 2 weeks and then off 1 week in a 3-week cycle. EGFR-TKIs were continue used. The primary endpoint was progression-free survival (PFS). The secondary endpoints included 6- and 12-month PFS rate, objective response rate (ORR), disease control rate (DCR), overall survival (OS) and safety. Results From July 2019 to December 2022, 120 patients were enrolled. The median PFS (mPFS) was 9.1 months (95% CI 6.8-11.7). The PFS rates at 6 and 12 months was 68.5% and 38.8% respectively. For 86 patients with first-line 1st /2nd generation EGFR-TKIs, the mPFS was 9.2 months (95% CI 6.7-12.6). For 32 patients with first-line 3rd generation EGFR-TKIs, the mPFS was 10.3 months (95% CI 6.1-13.3). Overall ORR and DCR were 6.7% (95% CI 2.9-12.7) and 87.5% (95% CI 80.2-92.8), respectively. 52.5% of patients had grade 3 or higher treatment-emergent adverse events (TEAEs). Conclusion Anlotinib in combination with continuation of EGFR-TKIs prolonged the clinical benefit of EGFR-TKIs, demonstrating favorable survival outcomes and manageable toxicity in NSCLC treated with EGFR-TKIs and had specific progression modes, such as gradual progression. Trial registration NCT04007835. Keywords: EGFR mutation, Anlotinib, Gradual progression, Oligo progression, Non-small cell lung cancer |
| ArticleNumber | 3 |
| Audience | Academic |
| Author | Wu, Yi-Long Zhou, Qing Cheng, Ying Hu, Yanping Jin, Gaowa Xu, Chong-Rui Xu, Ximing Chen, Hua-Jun Fan, Yun Tang, Shubin Cang, Shundong Yang, Nong Wu, Guowu Liu, Anwen Yu, Yan Tu, Hai-Yan Yang, Yi Ma, Rui |
| Author_xml | – sequence: 1 givenname: Hua-Jun surname: Chen fullname: Chen, Hua-Jun organization: Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University – sequence: 2 givenname: Hai-Yan surname: Tu fullname: Tu, Hai-Yan organization: Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University – sequence: 3 givenname: Yanping surname: Hu fullname: Hu, Yanping organization: Department of Thoracic Oncology, Hubei Cancer Hospital – sequence: 4 givenname: Yun surname: Fan fullname: Fan, Yun organization: Department of Thoracic Oncology, Zhejiang Cancer Hospital – sequence: 5 givenname: Guowu surname: Wu fullname: Wu, Guowu organization: Department of Medical Oncology, Meizhou People’s Hospital (Huangtang Hospital) – sequence: 6 givenname: Shundong surname: Cang fullname: Cang, Shundong organization: Department of Oncology, Henan Provincial People’s Hospital – sequence: 7 givenname: Yi surname: Yang fullname: Yang, Yi organization: Department of Thoracic Surgery, The Third People’s Hospital of Chengdu – sequence: 8 givenname: Nong surname: Yang fullname: Yang, Nong organization: Department of Oncology, The Second People’s Hospital of Hunan – sequence: 9 givenname: Rui surname: Ma fullname: Ma, Rui organization: Department of Thoracic Oncology, Liaoning Cancer Hospital & Institute – sequence: 10 givenname: Gaowa surname: Jin fullname: Jin, Gaowa organization: Department of Medical Oncology, Inner Mongolia Autonomous Region People’s Hospital – sequence: 11 givenname: Ximing surname: Xu fullname: Xu, Ximing organization: Department of Oncology, Renmin Hospital of Wuhan University – sequence: 12 givenname: Anwen surname: Liu fullname: Liu, Anwen organization: Department of Medical Oncology, The Second Affiliated Hospital of Nanchang University – sequence: 13 givenname: Shubin surname: Tang fullname: Tang, Shubin organization: Department of Oncology, The First People’s Hospital of Neijiang – sequence: 14 givenname: Ying surname: Cheng fullname: Cheng, Ying organization: Department of Oncology, Jilin Cancer Hospital – sequence: 15 givenname: Yan surname: Yu fullname: Yu, Yan organization: Department of Thoracic Medicine, Harbin Medical University Cancer Hospital – sequence: 16 givenname: Chong-Rui surname: Xu fullname: Xu, Chong-Rui organization: Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University – sequence: 17 givenname: Qing surname: Zhou fullname: Zhou, Qing organization: Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University – sequence: 18 givenname: Yi-Long surname: Wu fullname: Wu, Yi-Long email: syylwu@live.cn organization: Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute, Southern Medical University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39757186$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9k11r2zAUhs3oWD-2P7CLIRiMDuZWH7YsX40Q2i4srFCya6HIkqOiSKkkd-x37Q9Obro2GWMYLKHzvO_xOdY5Lg6cd6oo3iJ4hhCj5xERWNUlxFUJEa1pCV8UR6jJG9ZgfLCzPyyOY7yFkKIWw1fFIWmbuskWR8WvCdisRFRgNgMpGGGB10A465NxZgk2dojg4uryplx8nUVgHBDdvXBSdSB_TBnXwlogVX7ZwfVAjqEAfpi0An0Q3SDsJ-Ct6X1eAtj4pFwak2yC74OK0fjsqFPWPCdJQYm0ziA4nS6uv12ViEFyPpkvLm7KOYTo4-vipRY2qjeP60nx_fJiMf1Szq-vZtPJvJR1C1NJMYJaKSZhp5muiBA1JkrAtmai1RVc4kYzQpeI1EyjTqi6hpLkkKRE6CUlJ8Vs69t5ccs3waxF-Mm9MPzhwIeei5CMtIrrZU26SqgKElGpnJ-1kjRSj03WVI1en7dem2G5Vp3M5QVh90z3I86seO_vOUINxLAi2eH00SH4u0HFxNcmjq0XTvkhcoJqxBpK2xF9_xd664fgcq84wRAx1jJKn6le5AqM0z4nlqMpnzCMq4ogzDJ19g8qP51aG5kvpDb5fE_wYUewUsKmVfR2SPlfx33w3W5Lnnrx53JmAG8BGXyMQeknBEE-TgDfTgDPE8AfJoDDLCJbUcyw61V4rv0_qt9h6gRX |
| Cites_doi | 10.1186/s13045-020-00977-0 10.1016/j.lungcan.2020.11.020 10.1016/j.annonc.2022.02.003 10.1200/JCO.2017.73.9250 10.1093/annonc/mdy424.063 10.1016/j.esmoop.2023.101580 10.1038/s41467-020-20162-8 10.1186/s13045-022-01311-6 10.2147/CMAR.S363446 10.1186/s13045-022-01391-4 10.1056/NEJMoa2306434 10.1016/j.cllc.2013.10.001 10.1186/s12943-023-01823-w 10.1186/s13045-021-01127-w 10.1097/MD.0000000000023712 10.1186/s13045-016-0332-8 10.3892/ol.2023.13909 10.1038/bjc.2017.478 10.1111/1759-7714.14141 10.1016/j.jtho.2022.05.006 10.1186/s13045-016-0268-z 10.21037/atm-22-6101 10.1038/s43018-021-00195-8 10.1001/jamaoncol.2018.3039 10.1001/jamaoncol.2015.4921 10.1093/bib/bbs017 10.1093/bioinformatics/btp324 10.1016/j.lungcan.2022.05.011 10.1016/S1470-2045(15)00121-7 10.1016/j.ccell.2021.07.005 10.1038/nbt.2514 10.1016/j.lungcan.2012.09.016 10.1016/j.annonc.2022.10.352 10.1111/jcpt.13591 10.1177/17588359231193726 10.1200/JCO.2019.37.15_suppl.9020 10.1111/1759-7714.14819 10.1186/s13045-019-0759-9 10.1093/annonc/mdv597 10.21037/jtd.2018.07.19 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: 2025. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13045-024-01656-0 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Database Suite (ProQuest) ProQuest One Community College ProQuest Central Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals (Selected full-text) url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-8722 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_fb53d4ae403a4ec5989c37cf7186f6e6 PMC11702043 A822443128 39757186 10_1186_s13045_024_01656_0 |
| Genre | Multicenter Study Clinical Trial, Phase II Journal Article |
| GeographicLocations | China |
| GeographicLocations_xml | – name: China |
| GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABUWG ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP ~8M AAYXX ALIPV CITATION -5E -5G -A0 -BR 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7T5 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c590t-6210fee8c0df8f43aa523ea0958a9f40b27f836b1358f1dae550c3a9fc63afb63 |
| IEDL.DBID | M48 |
| ISSN | 1756-8722 |
| IngestDate | Wed Aug 27 01:29:24 EDT 2025 Thu Aug 21 18:34:53 EDT 2025 Thu Sep 04 23:22:41 EDT 2025 Fri Jul 25 10:29:51 EDT 2025 Sun Jun 15 06:15:22 EDT 2025 Tue Jun 10 20:53:52 EDT 2025 Thu May 22 21:23:31 EDT 2025 Wed Feb 19 02:02:11 EST 2025 Tue Jul 01 04:23:19 EDT 2025 Sat Sep 06 07:24:25 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | EGFR mutation Oligo progression Anlotinib Gradual progression Non-small cell lung cancer |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c590t-6210fee8c0df8f43aa523ea0958a9f40b27f836b1358f1dae550c3a9fc63afb63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://doi.org/10.1186/s13045-024-01656-0 |
| PMID | 39757186 |
| PQID | 3201889866 |
| PQPubID | 54946 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_fb53d4ae403a4ec5989c37cf7186f6e6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11702043 proquest_miscellaneous_3151876693 proquest_journals_3201889866 gale_infotracmisc_A822443128 gale_infotracacademiconefile_A822443128 gale_healthsolutions_A822443128 pubmed_primary_39757186 crossref_primary_10_1186_s13045_024_01656_0 springer_journals_10_1186_s13045_024_01656_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2025-01-05 |
| PublicationDateYYYYMMDD | 2025-01-05 |
| PublicationDate_xml | – month: 01 year: 2025 text: 2025-01-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of hematology and oncology |
| PublicationTitleAbbrev | J Hematol Oncol |
| PublicationTitleAlternate | J Hematol Oncol |
| PublicationYear | 2025 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | C Zhang (1656_CR16) 2021; 12 S Wang (1656_CR34) 2016; 9 H Thorvaldsdóttir (1656_CR26) 2013; 14 A Passaro (1656_CR30) 2022; 33 EB Garon (1656_CR40) 2023; 8 V Tumati (1656_CR20) 2018; 10 DR Gandara (1656_CR4) 2014; 15 K Shi (1656_CR37) 2022; 15 H Saito (1656_CR7) 2019; 20 A Passaro (1656_CR35) 2021; 2 B Han (1656_CR15) 2018; 4 YS Li (1656_CR33) 2023; 15 K Fu (1656_CR2) 2022; 15 L Zhang (1656_CR14) 2022; 33 M Schuler (1656_CR27) 2016; 27 K Chen (1656_CR39) 2021; 14 K Cibulskis (1656_CR25) 2013; 31 D Planchard (1656_CR31) 2023; 389 JJ Yang (1656_CR5) 2013; 79 Y Sun (1656_CR12) 2016; 9 B Han (1656_CR22) 2018; 118 Y Zhang (1656_CR23) 2021; 12 H Li (1656_CR24) 2009; 25 L Huang (1656_CR1) 2020; 13 L Zhang (1656_CR13) 2023; 22 M Wang (1656_CR18) 2023; 14 J Long (1656_CR9) 2022; 10 1656_CR32 TSK Mok (1656_CR29) 2017; 35 C Zhou (1656_CR41) 2019; 37 JC Soria (1656_CR28) 2015; 16 1656_CR36 M Johnson (1656_CR3) 2022; 170 N Yamamoto (1656_CR6) 2021; 151 H Kenmotsu (1656_CR43) 2022; 17 Q Wang (1656_CR38) 2019; 12 1656_CR8 Z Xu (1656_CR11) 2022; 14 Q Zhou (1656_CR42) 2021; 39 Y Chen (1656_CR17) 2023; 26 B Zhou (1656_CR19) 2022; 47 K Park (1656_CR21) 2016; 2 Y Yu (1656_CR10) 2021; 100 |
| References_xml | – volume: 13 start-page: 143 year: 2020 ident: 1656_CR1 publication-title: J Hematol Oncol doi: 10.1186/s13045-020-00977-0 – volume: 151 start-page: 20 year: 2021 ident: 1656_CR6 publication-title: Lung Cancer Jan doi: 10.1016/j.lungcan.2020.11.020 – volume: 33 start-page: 466 year: 2022 ident: 1656_CR30 publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.02.003 – volume: 35 start-page: 4027 year: 2017 ident: 1656_CR29 publication-title: J Clin Oncol doi: 10.1200/JCO.2017.73.9250 – ident: 1656_CR36 doi: 10.1093/annonc/mdy424.063 – volume: 8 start-page: 101580 year: 2023 ident: 1656_CR40 publication-title: ESMO Open doi: 10.1016/j.esmoop.2023.101580 – volume: 12 start-page: 11 year: 2021 ident: 1656_CR23 publication-title: Nat Commun doi: 10.1038/s41467-020-20162-8 – volume: 15 start-page: 94 issue: 1 year: 2022 ident: 1656_CR37 publication-title: J Hematol Oncol doi: 10.1186/s13045-022-01311-6 – volume: 14 start-page: 1891 year: 2022 ident: 1656_CR11 publication-title: Cancer Manag Res doi: 10.2147/CMAR.S363446 – volume: 15 start-page: 173 year: 2022 ident: 1656_CR2 publication-title: J Hematol Oncol doi: 10.1186/s13045-022-01391-4 – volume: 389 start-page: 1935 year: 2023 ident: 1656_CR31 publication-title: N Engl J Med doi: 10.1056/NEJMoa2306434 – volume: 15 start-page: 1 year: 2014 ident: 1656_CR4 publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2013.10.001 – volume: 22 start-page: 124 year: 2023 ident: 1656_CR13 publication-title: Mol Cancer doi: 10.1186/s12943-023-01823-w – volume: 14 start-page: 116 issue: 1 year: 2021 ident: 1656_CR39 publication-title: J Hematol Oncol doi: 10.1186/s13045-021-01127-w – volume: 100 start-page: e23712 year: 2021 ident: 1656_CR10 publication-title: Med (Baltim) doi: 10.1097/MD.0000000000023712 – volume: 9 start-page: 105 year: 2016 ident: 1656_CR12 publication-title: J Hematol Oncol doi: 10.1186/s13045-016-0332-8 – volume: 26 start-page: 323 year: 2023 ident: 1656_CR17 publication-title: Oncol Lett doi: 10.3892/ol.2023.13909 – volume: 118 start-page: 654 year: 2018 ident: 1656_CR22 publication-title: Br J Cancer doi: 10.1038/bjc.2017.478 – volume: 12 start-page: 2574 year: 2021 ident: 1656_CR16 publication-title: Thorac Cancer doi: 10.1111/1759-7714.14141 – volume: 17 start-page: 1098 year: 2022 ident: 1656_CR43 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2022.05.006 – volume: 9 start-page: 34 year: 2016 ident: 1656_CR34 publication-title: J Hematol Oncol doi: 10.1186/s13045-016-0268-z – volume: 10 start-page: 1334 year: 2022 ident: 1656_CR9 publication-title: Ann Transl Med doi: 10.21037/atm-22-6101 – volume: 2 start-page: 377 year: 2021 ident: 1656_CR35 publication-title: Nat Cancer doi: 10.1038/s43018-021-00195-8 – volume: 4 start-page: 1569 year: 2018 ident: 1656_CR15 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.3039 – volume: 2 start-page: 305 year: 2016 ident: 1656_CR21 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2015.4921 – volume: 14 start-page: 178 year: 2013 ident: 1656_CR26 publication-title: Brief Bioinform doi: 10.1093/bib/bbs017 – ident: 1656_CR32 – ident: 1656_CR8 – volume: 25 start-page: 1754 year: 2009 ident: 1656_CR24 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btp324 – volume: 170 start-page: 41 year: 2022 ident: 1656_CR3 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2022.05.011 – volume: 16 start-page: 990 year: 2015 ident: 1656_CR28 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00121-7 – volume: 39 start-page: 1279 year: 2021 ident: 1656_CR42 publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.07.005 – volume: 31 start-page: 213 year: 2013 ident: 1656_CR25 publication-title: Nat Biotechnol doi: 10.1038/nbt.2514 – volume: 79 start-page: 33 year: 2013 ident: 1656_CR5 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2012.09.016 – volume: 33 start-page: S1562 year: 2022 ident: 1656_CR14 publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.10.352 – volume: 20 start-page: 625 issue: 5 year: 2019 ident: 1656_CR7 publication-title: Oncol May – volume: 47 start-page: 643 year: 2022 ident: 1656_CR19 publication-title: J Clin Pharm Ther doi: 10.1111/jcpt.13591 – volume: 15 start-page: 175883592311937 year: 2023 ident: 1656_CR33 publication-title: Ther Adv Med Oncol doi: 10.1177/17588359231193726 – volume: 37 start-page: 9020 year: 2019 ident: 1656_CR41 publication-title: J Clin Oncol doi: 10.1200/JCO.2019.37.15_suppl.9020 – volume: 14 start-page: 873 year: 2023 ident: 1656_CR18 publication-title: Thorac Cancer doi: 10.1111/1759-7714.14819 – volume: 12 start-page: 63 issue: 1 year: 2019 ident: 1656_CR38 publication-title: J Hematol Oncol doi: 10.1186/s13045-019-0759-9 – volume: 27 start-page: 417 year: 2016 ident: 1656_CR27 publication-title: Ann Oncol doi: 10.1093/annonc/mdv597 – volume: 10 start-page: S2537 year: 2018 ident: 1656_CR20 publication-title: J Thorac Dis doi: 10.21037/jtd.2018.07.19 |
| SSID | ssj0061920 |
| Score | 2.4014533 |
| Snippet | Background
The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced... The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung... Background The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced... BackgroundThe study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small... Abstract Background The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 3 |
| SubjectTerms | Adult Aged Anlotinib Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Blood vessels Cancer Research Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Cell survival Chemotherapy Clinical medicine Clinical trials Disease control Disease Progression Drug dosages EGFR mutation Epidermal growth factor receptors ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Female Gradual progression Hematology Humans Indoles - administration & dosage Indoles - adverse effects Indoles - therapeutic use Kinases Lung cancer Lung cancer, Non-small cell Lung cancer, Small cell Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medicine Medicine & Public Health Middle Aged Mutation Non-small cell lung cancer Non-small cell lung carcinoma Oligo progression Oncology Oral administration Patients Pemetrexed Product development Progression-Free Survival Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Quinolines - administration & dosage Quinolines - adverse effects Quinolines - therapeutic use Response rates Small cell lung carcinoma Toxicity Tumors Tyrosine kinase inhibitors Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3LbtQw0EI9IC6IN4ECRkICRK06ceJ1jkvVbRfaIqGt1JvlOHa7UkhW-_gyfpAZJ1k2RYgLp0iZiWJ7xvOw50HIOzUalUmqPJNWlCw13jJTpJbxkmdl4mysAqXPL-TpZfrlKrvaafWFMWFteeB24Q59kYkyNS7lwqTOZrnKrcBaOrGSXrpQbJvnvHemWhmMXgHvU2SUPFzFeCHIQB8xTN8BH3qghkK1_j9l8o5Suh0weevWNCijyQNyv7Mi6bgd_UNyx9WPyN3z7p78Mfk5posb0E90OqWhLwdtPDV11azn9bygi2qzoscnk-9s9nW6ovOa9qEAtG5qtvphqorikT6tQBZQi6AlxSNber00mL11QJtqft3AY0kXzRpDjuAnIdirLfRBQ_PxnZ9sI9rph6PZt4sTBvQRh-MzMKfZGWixj0_I5eR4dnTKuvYMDKjA10yCt-idU5aXXvlUGANOrTNgsymT-5QXycgrIYtYZMrHpXHgDFkBICuF8YUUT8keTMo9J9TFFgzNwiey4KnjmSpK7zm4Zqkt47IYReRTTy29aKtw6OC9KKlb2mqgrQ601Twin5GgW0ysoB1eAF_pjq_0v_gqIm-QHXSbjrqVA3qMYbdgdSUqIu8DBkoC4ApruoQGmBLW1Bpg7g8wYQfbIbhnOd1JkJUWYJkplSsJI3m7BeOXGBVXu2YDOGCugTaTuYjIs5ZDt5MGOzPDuUREDXh3sCpDSD2_CfXFsRkRpkxH5KBn89_j-vuyv_gfy_6S3EuwwzIecmX7ZG-93LhXYPati9dhh_8CVkdRpA priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection (ProQuest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1rb9Mw0IIhIb4g3gQGGAkJELOa1InrfkJlWrfCNiTUSf1mOY7dVQpJadpfxh_kznlsGYJPkeprksud7-V7EPJOjkbZMJaOCcMzFmtnmE5jw8IsTLKhNZH0lD47FycX8ddFsmgCblWTVtnKRC-os9JgjHzAQVNJOZZCfF7_Yjg1Ck9XmxEat8mdCCwRHN0wWnQOF_oGYVsoI8WgivBYkIFWYljEA550Txn5nv1_S-Zrqulm2uSNs1OvkqYPyP3GlqSTmvgPyS1bPCJ3z5rT8sfk94SuL0FL0dmM-ukctHRUF3m5XRWrlK7zXUWPjqc_2PzbrKKrgrYJAbQoC1b91HlOMbBPc5AI1ODShmLgli43Gmu4DmiZr5YlXDZ0XW4x8Qge4lO-6nYf1I8gv_aQLq-dfjicfz8_ZkAlPpicglHNTkGXfXxCLqZH88MT1gxpYCYZh1smwGd01koTZk66mGsNrq3VYLlJPXZxmA5HTnKRRjyRLsq0BZfIcFgygmuXCv6U7AFS9jmhNjJgbqZuKNIwtmEi08y5EBy02GRRlo4C8qmlllrXvTiU92GkUDVtFdBWedqqMCBfkKAdJPbR9j-Um6VqtqVyacKzWNs45Dq2gJEcG46dmuCeTlgRkDfIDqouSu2kgZpg8i3YXkMZkPceAuUBcIXRTVkDoISdtXqQ-z1I2Memv9yynGrkSKWuuD4gb7tl_CfmxhW23AEMGG2g08SYB-RZzaEd0mBtJohLQGSPd3tfpb9SrC59l3EcSYSF0wE5aNn86r3-_dlf_B-Nl-TeECcoYxAr2Sd7283OvgKzbpu-9nv3D1ZuSJQ priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1db9Mw0IIhIV4Q3wQGGAkJELOWxInrPpZq3QrbkFAn7c2yHXurFJKqH7-MP8idk5RmwANPleJLk8vd-e58X4S8k4NBkWbSM2F5wTLtLdMmsywu4rxInU1koPTZuTi5yL5c5pdtmxyshdmN3ydSHK4SDOUx0CQMC2_A-71N7uRwEbl5LMbdrot-QNwVxfz1vp7iCf35_9yFd9TQzRTJG3HSoH4mD8j91m6ko4bQD8ktVz0id8_ayPhj8nNEF9egkeh0SsMkDlp7qquyXs-ruaGLcrOiR8eT72z2dbqi84p2wX8K_j9b_dBlSfEQn5Yg_dTi0pLiIS29Wmqs1zqgdTm_quFnSRf1GpOM4CEhvatp7UHDuPGdh2xz2OmH8ezb-TEDivDD0SkY0OwU9NbHJ-RicjQbn7B2IAOz-TBeMwH-oXdO2rjw0mdca3BjnQYrTeqhz2KTDrzkwiQ8lz4ptAP3x3JYsoJrbwR_SvYAKfecUJdYMC2NT4WJMxfn0hTex-CMZbZICjOIyKeOWmrR9N1QwV-RQjW0VUBbFWir4oh8RoJuIbFndrgArKRaEVTe5LzItMtirjMHGMmh5diVCf7TCyci8gbZQTUFqFvJVyNMtAU7K5UReR8gUPaBK6xuSxgAJeyi1YPc70GCzNr-csdyqt0zVoqDLSblUAp4k7fbZbwT8-AqV28ABgw00F9iyCPyrOHQLdJgWeaIS0Rkj3d7X6W_Us2vQ0dxHD-ERdIROejY_Pd7_fuzv_g_8JfkXorTk_EAK98ne-vlxr0Ck25tXgdZ_gWP_0FP priority: 102 providerName: Springer Nature |
| Title | A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001) |
| URI | https://link.springer.com/article/10.1186/s13045-024-01656-0 https://www.ncbi.nlm.nih.gov/pubmed/39757186 https://www.proquest.com/docview/3201889866 https://www.proquest.com/docview/3151876693 https://pubmed.ncbi.nlm.nih.gov/PMC11702043 https://doaj.org/article/fb53d4ae403a4ec5989c37cf7186f6e6 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1db9Mw0NqHhHhBfBMYxUhIPLCwJHYc9wGhrmpZizahsUp7sxzH7iqFpKStBL-FP8vZScoyBk-R7Eti--58d_Z9IPSGJ0kWUW58pkjmU2mUL1Oq_CAL4izSKuQO06dn7GRGp5fx5Q5qyx01C7i61bSz9aRmVf7-x_efH4HhPziG5-xoFdrrPh-kjW-Dc8BC3kX77r7IuvLR7a2CtRXqAEmA4UkUtUE0t36jI6hcPv-_d-1rYuumS-WNe1Unrsb30b1Gz8SDmjAeoB1dPER3Tpub9Efo1wAvr0CC4ckEu8oduDRYFnm5XhSLFC_zzQqPPo3P_YvPkxVeFLh1FsBFWfirbzLPsT30xznsFljZrgrbQ108r6SN7zrEZb6Yl_Co8LJcW6ck-IlzB6tTgWBXnvzaT7Y-74_RbDy6GJ74TaEGX8X9YO0zsBuN1lwFmeGGEinBvNUStDcu-4YGaZQYTlgakpibMJMazCJFoEsxIk3KyBO0B4PXzxDWoQKVMzURSwOqg5inmTEBGGlUZWGWJh5612JFLOt8HMLZMZyJGocCcCgcDkXgoWOLuC2kzaXtGspqLhrWFCaNSUalpgGRVMOMeF8Rm60JvmmYZh56ZdEu6sDU7Y4gBtYBF_SviHvorYOwVArYV7IJbYAp2exaHciDDiTwsup2t6QlWlYQBHQ0zvucwUheb7vtm9Y_rtDlBmBAcQO5xvrEQ09rStxOGjTO2M7FQ7xDo51V6fYUiyuXadyWJbLB0x46bMn5z7j-vezP_z_LF-huZKso24Os-ADtrauNfgmq3Trtod3kMumh_cFg-nUKz-PR2ZdzaB2yYc8dl_QcR_8GonxNbA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1db9Mw0BqdBLwgvgkMZiQQIGYtjRPXfZhQN7a1rCto6qS9Gcext0olKW0nxO_ind_GnZt0yxC87alS75r0cpf78H0R8kq2WlkUS8eE4RmLtTNMp7FhYRYmWWRNU3pOHw5E9zj-dJKcrJDfVS8MllVWOtEr6qwweEa-ycFSSdmWQnyYfGe4NQqzq9UKDV2uVsi2_IixsrHjwP78ASHcbKv3Efj9Oor2doc7XVZuGWAmaYdzJiDocdZKE2ZOuphrDbGZ1eB6SN12cZhGLSe5SJs8ka6ZaQs-veEAMoJrlwoO171BVmM8QGmQ1e3dwZejyhZgdBJWrTpSbM6amJhkYBcZthFBLF8zh35rwN-24ZJxvFq4eSV7643i3l1yp_RmaWchfvfIis3vk5uHZb7-AfnVoZMzsJO016N-PwgtHNX5uJiP8lFKJ-PzGd3d3ztiw4PejI5yWpUk0LzI2eybHo8pphboGHQSNQiaUjw6pqdTjV1kG7QYj04L-JjSSTHH0ie4iS86WwwcoX4J-qWbLCvr6dud4efBPgM54ZudPrj1rA_W9N1DcnwtDHxEGkCUfUKobRpweFMXiTSMbZjINHMuhBAxNlkzS1sBeV9xS00W00CUj6KkUAveKuCt8rxVYUC2kaFLTJzk7b8opqeqVAzKpQnPYm3jkOvYAkWybTjOioJrOmFFQNZRHNSiLXapj1QHy3_B-4tkQN54DNRIIBVGl40VQBLO9qphrtUwQZOYOrgSOVVqspm6eO8C8nIJxl9idV5ui3PAAbcRrKpo84A8XkjokmjwdxOkJSCyJru1p1KH5KMzP-cclyJh63ZANioxv_hf_37sT_9Pxjq51R0e9lW_Nzh4Rm5HuM8Zj9SSNdKYT8_tc3Ay5-mL8k2m5Ot1K48_vciM8A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3bbtMw1IJNmnhB3AkMZiQkQMxqEieu8xjGurXrCoJO2pvlOHZXKSRVL1_GD3LsJKUZ8MBTpPjkcnyOz8U-F4Te8n4_DyNuCFM0J5E0isgsUsTP_TgPtQq4o_TlhJ1fRaPr-Honi99Fu7dHknVOg63SVK57i9zUS5yz3iqwB3wE9Aux6TjgE99F-zxOEnC_9tN09H3USmPrH_htssxfn-woJFe3_0_pvKOebodO3jo_dWpp8ADdb-xJnNYM8BDd0eUjdHDZnJg_Rj9TvLgBTYWHQ-w6dODKYFkW1XpezjO8KDYrfHo2-EamF8MVnpe4DQrAZVWS1Q9ZFNhu7uMCpAJWdmiJ7eYtni2lzeM6xlUxn1VwWeJFZefQfsSFfdUlP7BrQ77zkW1sO35_Mv0yOSNAKdpLx2BYkzHosw9P0NXgdHpyTppGDUTFib8mDPxGozVXfm64iaiU4N5qCdYbl4mJ_CzsG05ZFtCYmyCXGtwiRWFIMSpNxuhTtAdI6ecI60CByZmZkGV-pP2YZ7kxPjhpkcqDPOt76GNLLbGo63EI58dwJmraCqCtcLQVvoc-WYJuIW0tbXejWs5EszSFyWKaR1JHPpWRBox4oqit1gTvNEwzDx1ZdhB1YupWIojUBuCC_RVyD71zEFYmAFco2aQ2AEq2ulYH8rADCWtZdYdblhONLFkJCjYa5wln8CdvtsP2SRsfV-pqAzBguIFeYwn10LOaQ7dIg8UZW1w8xDu825mV7kg5v3GVxm1bIps87aHjls1__9e_p_3F_4EfoYOvnwdiPJxcvET3Qttg2e5xxYdob73c6Fdg9a2z183C_gX72k38 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+phase+II+trial+of+anlotinib+plus+EGFR-TKIs+in+advanced+non-small+cell+lung+cancer+with+gradual%2C+oligo%2C+or+potential+progression+after+EGFR-TKIs+treatment&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Chen%2C+Hua-Jun&rft.au=Tu%2C+Hai-Yan&rft.au=Hu%2C+Yanping&rft.au=Fan%2C+Yun&rft.date=2025-01-05&rft.pub=BioMed+Central+Ltd&rft.issn=1756-8722&rft.eissn=1756-8722&rft.volume=18&rft.issue=1&rft_id=info:doi/10.1186%2Fs13045-024-01656-0&rft.externalDocID=A822443128 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon |